GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)
Brief description of study
This trial is to evaluate the safety and efficacy of adding GMCI to standard of care in patients with stage III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Non Small Lung Cancer,Non Small Lung Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female 18 years of age or older Non Small Lung cancer
Updated on
09 Mar 2024.
Study ID: 844087
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting